Transfer factor potentiates cellular immunity and induces interferon. It was because of these properties that transfer factor was tried in 17 patients with recurrent herpes simplex types 1 and 2. Transfer factor was administered in doses ranging from 5 to 10 U/m2 i.m. The interval between injections varied from 1 week to 3 months. 16 patients could be evaluated clinically in whom the recurrence rate decreased from 10.7 ± 6.1 to 2.1 ± 2.5 (mean SD). The reduction was statistically significant. 8 patients were completely free of disease while the other 8 had a reduced number of episodes during the period of observation. 7 patients had abnormal T cell function as reflected by the low number of T cells or low lymphocyte transformation. Statistically significant improvement in the T cell function was observed. Delayed hypersensitivity skin test reactions also improved significantly.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.